RNA - Why Avidity Biosciences Shares Are Trading Higher Wednesday | Benzinga
Avidity Biosciences (NASDAQ:RNA) stock is moving higher Wednesday following the company’s announcement that the Phase 1/2 FORTITUDE trial yielded positive results.
The Details: The 39 patient trial was in relation to treating facioscapulohumeral muscular dystrophy (FSHD) with delpacibart braxlosiran.
Data from the trial showed functional improvements across patients with the disease, greater than 50% mean reductions in DUX4 regulated genes and the medicine appears to be well tolerated.
“Data from ...